Dosing strategies for gene therapies

The original goal of gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, with promising follow-up data evidenced. However, in some instances, including gene therapies for hemophilia, a single dose may not be enough, and redosing may be required.

In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for ’one-and-done’ versus redosing therapies.

Open PDF

Return to Insights Center

Related Insights


New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023


New Medicines, Novel Insights: Achieving patient-guided drug development

Oct 30, 2023


SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change

Aug 24, 2022


Regulatory, clinical and logistics challenges of ATMPs in clinical research

Apr 22, 2021


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021


Three strategies for articulating a coherent product value story

Dec 18, 2021


Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022


How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022


Chris Learn joins Parexel as Head of the Cell and Gene Center of Excellence

Apr 4, 2022


Overview of China's Market Approval Policy Med Insurance Payment System

Apr 7, 2022


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


Preparing for a new era in European Market Access

Jul 22, 2022